Program Code: SCF-DBI-PECMO-HEMO-0006**
Operational Window: Cannulation → Active ECMO Support → Decannulation → Recovery Phase
Primary Objective: Preserve hemostatic adaptation, prevent thrombosis, minimize bleeding complications, protect endothelial integrity, maintain circuit performance, and optimize recovery biology during extracorporeal support.
SECTION 6.1
CLINICAL POSITIONING
Traditional ECMO Hemostasis Model
Focuses on:
Anticoagulation
Bleeding control
Circuit thrombosis
Laboratory monitoring
SCF-DBI Hemostasis Model
Hemostasis is viewed as:
Dynamic Thromboimmune-Endothelial Adaptation System
integrating:
Coagulation biology
Endothelial biology
Platelet biology
Immune biology
Recovery biology
Core Principle
The goal is not maximal anticoagulation.
The goal is preservation of adaptive hemostatic balance.
SECTION 6.2
HEMOSTATIC INTELLIGENCE HIERARCHY
Tier I
Coagulation Stability
Maintain:
Controlled clot formation
Controlled clot resolution
Circuit patency
Tier II
Platelet-Endothelial Adaptation
Maintain:
Platelet functionality
Glycocalyx integrity
Microvascular flow
Tier III
Thromboimmune Stability
Maintain:
Controlled inflammation
Controlled complement activation
Recovery signaling
Tier IV
Recovery Hemostasis
Maintain:
Tissue repair
Vascular repair
Recovery progression
SECTION 6.3
RHENOVA HEMOSTATIC PRESERVATION PLATFORM
Strategic Goal
Prevent transition from adaptive coagulation to pathologic thrombosis or bleeding.
Platform Components
Component 1
Coagulation Surveillance
Component 2
Platelet Surveillance
Component 3
Circuit Surveillance
Component 4
Endothelial Surveillance
Component 5
Recovery Hemostasis Monitoring
Primary Output
Hemostatic Adaptation Score (HAS)
SECTION 6.4
ECMO COAGULATION SURVEILLANCE SYSTEM
Monitoring Domains
Coagulation activation
Anticoagulation effectiveness
Clot propagation
Fibrinolytic activity
Recovery progression
Core Variables
ACT
Anti-Xa
PT
INR
aPTT
Fibrinogen
D-dimer
Platelet count
Primary Output
Coagulation Intelligence Index (CII)
SECTION 6.5
CIRCUIT THROMBOSIS PREVENTION FRAMEWORK
Clinical Positioning
Circuit thrombosis represents:
Artificial Surface Adaptation Failure
High-Risk Regions
Oxygenator
Pump head
Venous limb
Arterial limb
Cannulation interfaces
Surveillance Variables
Pressure gradients
Flow disturbances
Oxygenator performance
Visual clot inspection
Hemolysis indicators
Primary Output
Circuit Integrity Score (CIS)
SECTION 6.6
PLATELET–ENDOTHELIUM INTERACTION MODEL
Strategic Position
Platelets function as:
Repair Signaling Cells
not solely clotting cells.
Domains
Platelet Function
Activation
Adhesion
Aggregation
Endothelial Function
Glycocalyx integrity
Barrier function
Anti-thrombotic signaling
Interaction Function
Repair signaling
Recovery signaling
Inflammatory modulation
Primary Output
Platelet-Endothelial Adaptation Score (PEAS)
SECTION 6.7
BLEEDING INTELLIGENCE SURVEILLANCE SYSTEM
Clinical Positioning
Bleeding is viewed as:
Hemostatic Adaptation Failure
Surveillance Domains
Surgical bleeding
Cannulation bleeding
Intracranial bleeding
Gastrointestinal bleeding
Diffuse coagulopathy
Bleeding Severity Classification
Grade I
Minor
Grade II
Moderate
Grade III
Major
Grade IV
Life-threatening
Primary Output
Bleeding Vulnerability Index (BVI)
SECTION 6.8
THROMBOINFLAMMATORY ADAPTATION FRAMEWORK
Clinical Positioning
Thrombosis and inflammation are biologically linked.
Monitoring Domains
Cytokine activation
Coagulation activation
Complement activation
Endothelial activation
Core Variables
CyAI
STRI
EII
D-dimer
Fibrinogen
Primary Output
Thromboinflammatory Adaptation Index (TAI)
SECTION 6.9
ECMO ANTICOAGULATION COMMAND CENTER
Strategic Objective
Maintain individualized anticoagulation balance.
Operational Domains
Circuit protection
Bleeding prevention
Thrombosis prevention
Recovery preservation
Risk States
Green
Balanced adaptation
Yellow
Vulnerable adaptation
Orange
Threatened adaptation
Red
Critical imbalance
SECTION 6.10
HEMOLYSIS SURVEILLANCE PROGRAM
Clinical Positioning
Hemolysis represents:
Mechanical Blood Trauma Syndrome
Monitoring Variables
Plasma free hemoglobin
LDH
Bilirubin
Circuit pressures
Renal function
Hemolysis Risk Classification
Mild
Moderate
Severe
Critical
Primary Output
Hemolysis Burden Score (HBS)
SECTION 6.11
ECMO TRANSFUSION INTELLIGENCE FRAMEWORK
Strategic Position
Blood products are viewed as:
Recovery Support Tools
with potential adaptive consequences.
Surveillance Domains
Oxygen carrying capacity
Hemostatic support
Immune modulation
Endothelial effects
Monitoring Variables
Hemoglobin
Platelets
Fibrinogen
STRI
EII
Primary Output
Transfusion Adaptation Score (TAS)
SECTION 6.12
RHENOVA HEMOSTATIC RECOVERY ARCHITECTURE
Recovery Domain 1
Coagulation Recovery
Recovery Domain 2
Endothelial Recovery
Recovery Domain 3
Microvascular Recovery
Recovery Domain 4
Immune Recovery
Recovery Domain 5
Functional Recovery
Recovery Outputs
HAS
PEAS
TAI
CRIS
SECTION 6.13
DAILY HEMOSTATIC INTELLIGENCE ROUNDS
Required Participants
ECMO Intensivist
Perfusion Specialist
Hematologist
Pharmacist
Nursing Leadership
Laboratory Medicine
Daily Review
HAS
CIS
PEAS
TAI
HBS
Recovery trajectory
SECTION 6.14
HEMOSTATIC ESCALATION MATRIX
Level 1
Enhanced Monitoring
Triggers:
Mild laboratory abnormalities
Minor bleeding
Level 2
Focused Intervention
Triggers:
HAS decline >10%
PEAS decline >10%
Level 3
Multidisciplinary Escalation
Triggers:
Progressive thrombosis
Major bleeding
TAI decline >15%
Level 4
Advanced Hemostatic Preservation Activation
Triggers:
HAS <50
Oxygenator dysfunction
Significant hemolysis
Level 5
Hemostatic Rescue Pathway
Triggers:
HAS <40
Life-threatening hemorrhage
Catastrophic thrombosis
SECTION 6.15
HEMOSTATIC PRESERVATION SUCCESS ENDPOINTS
Clinical
Reduced circuit thrombosis
Reduced major bleeding
Reduced hemolysis
Reduced oxygenator failure
Recovery
Improved organ recovery
Reduced transfusion burden
Improved rehabilitation outcomes
Biological Intelligence
HAS >80
CIS >80
PEAS >80
TAI >80
EII >80
CRIS >80
Sustained hemostatic resilience
PAGE 6 COMPLETION
Next Page (Page 7):